Cyclophosphamide effect on coccidioidomycosis in the rat

Coccidioidomycosis is a systemic mycosis, endemic in arid areas of the American continent. The rat was employed as an experimental host, since it had been shown to reproduce human lesions and present a chronic course of disease with granulomas mainly restricted to lungs. Given the influence of immunosuppressive therapy on the clinical course of human coccidioidomycosis, we studied the effect of cyclophosphamide (CY) in the experimental rat model. Accordingly, animals were inoculated with 400 Coccidioides immitis arthroconidia of the Acosta strain, by intracardiacal route. As single CY doses failed to alter the course of disease, three schedules were used: A) 4 daily doses of 20 mg/kg each, prior to C. immitis inoculation; B) 4 similar daily doses after infection; and C); 6 doses of 20 mg/kg each, given from day +1 to +4, then on days +8 and +9, post infection (pi), taking day 0 as the time of fungal inoculation. The first two schedules inhibited antibody formation up to day 28 pi, without modifying cellular response to coccidioidin as measured by foodpad swelling. Initially, there was greater fungal spread than in controls receiving C. immitis alone, which proved self-limiting in the latter. In contrast, schedule C led to 559r mortality, with both humoral and cellular response abrogation, accompanied by extensive C. immitis dissemination. Histology disclosed significant alterations, such as the persistence of primary infection sporangia, corresponding to the acute stage of coccidioidomycosis in the absence of granuloma development. Therefore, the observed depression in cellular immunity seems responsible for the lack of inflammatory reaction capable of restricting sporangia proliferation in tissues which, in turn, enhances pathogen spread and mortality rate.El propósito de este trabajo fue estudiar el efecto de la inmunosupresión causada por la droga ciclofosfamida (CY) sobre la infección de la rata con Coccidioides immitis por vía intracardíaca. Este huésped fue empleado como modelo experimental, ya que presenta una evolución de la enfermedad semejante a la del hombre, alcanzando una etapa crónica con granulomas principalmente restringidos a los pulmones. Se utilizaron tres esquemas de CY: A) 4 dosis de 20 mg/kg cada una, antes de la inoculación de Ci; B) 4 dosis de igual cantidad de CY, luego de la infección; y C) 6 dosis de 20 mg/kg cada una, administradas desde el día +1 hasta +4 y continuando los días + 8 y +9 post-infección (pi). Los dos primeros esquemas inhibieron la formación de anticuerpos hasta el día 28 pi, sin modificar la respuesta celular a la coccidioidina, medida como hinchazón de la almohadilla plantar. Se observó una mayor diseminación fúngica inicial, autolimi-tándose más tarde. Por el contrario, el esquema C provocó un 55% de mortalidad, disminución de la respuesta humoral y celular, acompañada de una extensa diseminación del Ci. La histología mostró alteraciones significativas, tales como persistencia de esporangios de primoinfección, correspondientes al estadio agudo de la coccidioidomicosis, con ausencia de desarrollo de granulomas. Por lo tanto, la depresión observada en la respuesta celular debido al tratamiento con CY sería la responsable de la ausencia de la reacción inflamatoria capaz de restringir la proliferación de esporangios en los tejidos, lo cual a su vez favorece la diseminación del microorganismo patógeno y el aumento de morta lidad

How long do nosocomial pathogens persist on inanimate surfaces? A systematic review

BACKGROUND: Inanimate surfaces have often been described as the source for outbreaks of nosocomial infections. The aim of this review is to summarize data on the persistence of different nosocomial pathogens on inanimate surfaces. METHODS: The literature was systematically reviewed in MedLine without language restrictions. In addition, cited articles in a report were assessed and standard textbooks on the topic were reviewed. All reports with experimental evidence on the duration of persistence of a nosocomial pathogen on any type of surface were included. RESULTS: Most gram-positive bacteria, such as Enterococcus spp. (including VRE), Staphylococcus aureus (including MRSA), or Streptococcus pyogenes, survive for months on dry surfaces. Many gram-negative species, such as Acinetobacter spp., Escherichia coli, Klebsiella spp., Pseudomonas aeruginosa, Serratia marcescens, or Shigella spp., can also survive for months. A few others, such as Bordetella pertussis, Haemophilus influenzae, Proteus vulgaris, or Vibrio cholerae, however, persist only for days. Mycobacteria, including Mycobacterium tuberculosis, and spore-forming bacteria, including Clostridium difficile, can also survive for months on surfaces. Candida albicans as the most important nosocomial fungal pathogen can survive up to 4 months on surfaces. Persistence of other yeasts, such as Torulopsis glabrata, was described to be similar (5 months) or shorter (Candida parapsilosis, 14 days). Most viruses from the respiratory tract, such as corona, coxsackie, influenza, SARS or rhino virus, can persist on surfaces for a few days. Viruses from the gastrointestinal tract, such as astrovirus, HAV, polio- or rota virus, persist for approximately 2 months. Blood-borne viruses, such as HBV or HIV, can persist for more than one week. Herpes viruses, such as CMV or HSV type 1 and 2, have been shown to persist from only a few hours up to 7 days. CONCLUSION: The most common nosocomial pathogens may well survive or persist on surfaces for months and can thereby be a continuous source of transmission if no regular preventive surface disinfection is performed

Thymosin restoration of cellular immunity to Blastomyces dermatitidis in T-cell-depleted mice.

The immunopotentiating properties of thymosin in thymectomized, lethally irradiated, bone marrow-reconstituted mice (ThyXBM) were characterized, using footpad sensitivity to Blastomyces dermatitidis. Normal mice were shown to exhibit increasing delayed-type hypersensitivity responses to killed yeast cells of B. dermatitidis after injections of the organism on days 0 and 7, as measured by footpad swelling tests. The footpad response of normal thymosin-treated mice was similar to that of normal, non-thymosin-treated mice. ThyXBM mice were unable to elicit a footpad response when similarly injected and footpad tested with B. dermatitidis. Thymosin-treated ThyXBM mice responded to footpad testing at a level that was 62% greater than the response seen in non-thymosin-treated ThyXBM mice. This peak response occurred on day 12. The results indicated that thymosin was unable to enhance immune responses of normal intact mice but could restore immunocompetence in a T-cell-depleted host, as measured by footpad sensitivity to B. dermatitidis